This company has been marked as potentially delisted and may not be actively trading. Mirati Therapeutics (MRTX) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Mirati Therapeutics Short Interest DataMirati Therapeutics (MRTX) has a short interest of 4.39 million shares. This marks a -40.68% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.0, indicating that it would take 2.0 days of the average trading volume of 2.76 million shares to cover all short positions.Current Short Interest4,390,000 sharesPrevious Short Interest7,400,000 sharesChange Vs. Previous Month-40.68%Dollar Volume Sold Short$257.91 millionShort Interest Ratio2.0 Days to CoverLast Record DateDecember 31, 2023Outstanding Shares70,150,000 sharesPercentage of Shares Shorted6.26%Today's Trading Volume0 sharesAverage Trading Volume2,758,857 sharesToday's Volume Vs. Average0% Short Selling Mirati Therapeutics? Sign up to receive the latest short interest report for Mirati Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMRTX Short Interest Over TimeMRTX Days to Cover Over TimeMRTX Percentage of Float Shorted Over Time Mirati Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20234,390,000 shares $257.91 million -40.7%N/A2 $58.75 12/15/20237,400,000 shares $427.65 million +56.1%N/A3.3 $57.79 11/30/20234,740,000 shares $269.00 million -22.2%N/A2.1 $56.75 11/15/20236,090,000 shares $342.32 million +31.8%N/A2.7 $56.21 10/31/20234,620,000 shares $256.55 million -0.9%N/A2 $55.53 10/15/20234,660,000 shares $260.73 million -45.8%N/A2.1 $55.95 9/30/20238,590,000 shares $374.18 million -5.1%N/A4.4 $43.56 9/15/20239,050,000 shares $299.10 million -4.3%N/A7 $33.05 8/31/20239,460,000 shares $351.91 million -1.8%N/A8 $37.20 8/15/20239,630,000 shares $382.60 million +19.6%N/A7.7 $39.73 Get the Latest News and Ratings for MRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20238,050,000 shares $243.67 million -7.9%N/A6.9 $30.27 7/15/20238,740,000 shares $309.66 million +1.6%N/A8.5 $35.43 6/30/20238,600,000 shares $310.72 million +6.6%N/A8.3 $36.13 6/15/20238,070,000 shares $314.49 million +13.5%N/A7.7 $38.97 5/31/20237,110,000 shares $264.21 million +5.2%N/A6.8 $37.16 5/15/20236,760,000 shares $334.21 million -14.8%N/A6.9 $49.44 4/30/20237,930,000 shares $351.38 million -13.6%N/A7.9 $44.31 4/15/20239,180,000 shares $360.32 million -0.9%N/A8.6 $39.25 3/31/20239,260,000 shares $344.29 million +7.7%N/A8.3 $37.18 3/15/20238,600,000 shares $371.26 million -2.4%N/A6.8 $43.17 2/28/20238,810,000 shares $403.85 million -3.9%N/A5 $45.84 2/15/20239,170,000 shares $446.67 million -3.9%N/A4.9 $48.71 1/31/20239,540,000 shares $509.53 million -10.3%N/A4.9 $53.41 1/15/202310,630,000 shares $458.05 million +1.0%N/A5.7 $43.09 12/30/202210,530,000 shares $477.11 million +6.6%N/A5.9 $45.31 12/15/20229,880,000 shares $420.30 million +30.0%N/A5.9 $42.54 11/30/20227,600,000 shares $694.49 million -5.9%N/A5.8 $91.38 11/15/20228,080,000 shares $585.80 million +4.5%N/A8.4 $72.50 10/31/20227,730,000 shares $520.38 million -2.3%N/A10 $67.32 10/15/20227,910,000 shares $528.78 million +2.5%N/A9.4 $66.85 9/30/20227,720,000 shares $539.16 million -3.4%N/A8.4 $69.84 9/15/20227,990,000 shares $659.10 million +7.3%N/A8.1 $82.49 8/31/20227,450,000 shares $603.67 million -1.6%N/A6.7 $81.03 8/15/20227,570,000 shares $653.44 million +8.5%N/A4.8 $86.32 7/31/20226,980,000 shares $449.51 million -13.3%13.7%4.3 $64.40 7/15/20228,050,000 shares $483.16 million -2.2%24.0%5.2 $60.02 6/30/20228,230,000 shares $552.48 million +46.7%24.5%5.6 $67.13 6/15/20225,610,000 shares $302.66 million +19.1%16.7%4 $53.95 5/31/20224,710,000 shares $184.44 million -9.6%9.2%3.9 $39.16 5/15/20225,210,000 shares $296.14 million +24.1%10.2%7.1 $56.84Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 4/30/20224,200,000 shares $259.52 million +14.1%8.2%5.5 $61.79 4/15/20223,680,000 shares $301.54 million +10.8%7.2%5.2 $81.94 3/31/20223,320,000 shares $272.97 million +6.8%6.5%4.7 $82.22 3/15/20223,110,000 shares $240.47 million -7.2%6.1%4.5 $77.32 2/28/20223,350,000 shares $295.77 million +12.8%7.0%5 $88.29 2/15/20222,970,000 shares $318.95 million +2.1%6.2%4.6 $107.39 1/31/20222,910,000 shares $347.16 million +11.1%6.1%5 $119.30 1/15/20222,620,000 shares $325.69 million -4.4%5.5%4.9 $124.31 12/31/20212,740,000 shares $401.93 million -11.0%5.8%5.6 $146.69 12/15/20213,080,000 shares $434.22 million +14.1%6.5%6.1 $140.98 11/30/20212,700,000 shares $369.28 million -16.2%5.7%4.9 $136.77 11/15/20213,220,000 shares $453.34 million -16.6%6.8%5.9 $140.79 10/29/20213,860,000 shares $729.62 million -5.4%8.1%8.3 $189.02 10/15/20214,080,000 shares $727.38 million +1.5%8.6%9.3 $178.28 9/30/20214,020,000 shares $711.18 million +20.4%8.5%9.2 $176.91 9/15/20213,340,000 shares $561.39 million -7.5%7.0%6.6 $168.08 8/31/20213,610,000 shares $612.73 million -0.6%7.6%8.1 $169.73 8/13/20213,630,000 shares $508.82 million No Change7.6%8.2 $140.17 7/30/20213,630,000 shares $581.02 million +0.3%7.6%7.5 $160.06 7/15/20213,620,000 shares $574.46 million +5.2%7.4%6.2 $158.69 6/30/20213,440,000 shares $555.66 million -28.0%7.1%5.7 $161.53 6/15/20214,780,000 shares $796.35 million +4.4%9.8%9.3 $166.60 5/28/20214,580,000 shares $724.33 million +2.2%9.4%9.1 $158.15 5/14/20214,480,000 shares $693.32 million +6.7%N/A8.9 $154.76 4/30/20214,200,000 shares $690.94 million +11.7%N/A8.3 $164.51 4/15/20213,760,000 shares $607.09 million -3.3%N/A8.8 $161.46 3/31/20213,890,000 shares $645.62 million +2.9%N/A9.1 $165.97 3/15/20213,780,000 shares $718.16 million +3.3%N/A8.8 $189.99 2/26/20213,660,000 shares $715.90 million +6.4%N/A8.6 $195.60 2/12/20213,440,000 shares $726.63 million -9.7%N/A8.2 $211.23 1/29/20213,810,000 shares $776.74 million -0.8%N/A8.9 $203.87 1/15/20213,840,000 shares $820.80 million +1.1%N/A7.7 $213.75 12/31/20203,800,000 shares $833.30 million -4.5%N/A7.8 $219.29 12/15/20203,980,000 shares $934.70 million -1.7%N/A8.1 $234.85 11/30/20204,050,000 shares $941.79 million +1.3%N/A7.6 $232.54 11/15/20204,000,000 shares $916 million +7.0%N/A7.5 $229.00 10/30/20203,740,000 shares $822.69 million -13.6%N/A7.2 $219.97 10/15/20204,330,000 shares $829.54 million -3.8%N/A9.8 $191.58 9/30/20204,500,000 shares $747.23 million -5.7%N/A10.9 $166.05 9/15/20204,770,000 shares $751.99 million -0.6%N/A11.3 $157.65 8/31/20204,800,000 shares $716.98 million -1.6%N/A13 $149.37 8/14/20204,880,000 shares $677.10 million -3.4%N/A12.3 $138.75 7/31/20205,050,000 shares $612.62 million +1.8%N/A12 $121.31 7/15/20204,960,000 shares $596.64 million -0.6%N/A10.3 $120.29 MRTX Short Interest - Frequently Asked Questions What is Mirati Therapeutics' current short interest? Short interest is the volume of Mirati Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 4,390,000 shares of MRTX short. Learn More on Mirati Therapeutics' current short interest. What is a good short interest ratio for Mirati Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MRTX shares currently have a short interest ratio of 2.0. Learn More on Mirati Therapeutics's short interest ratio. Is Mirati Therapeutics' short interest increasing or decreasing? Mirati Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 4,390,000 shares, a decrease of 40.7% from the previous total of 7,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Mirati Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Mirati Therapeutics: Intra-Cellular Therapies, Inc. (2.58%), Zymeworks Inc. (3.24%), Chimerix, Inc. (4.27%), Avid Bioservices, Inc. (18.17%), Revance Therapeutics, Inc. (4.32%), Checkpoint Therapeutics, Inc. (6.19%), Aerovate Therapeutics, Inc. (21.72%), 2seventy bio, Inc. (5.37%), Acelyrin, Inc. (4.87%), Procaps Group S.A. (0.12%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: General Motors Company ($4.15 billion), T-Mobile US, Inc. ($3.92 billion), TC Energy Corporation ($3.66 billion), Charter Communications, Inc. ($3.35 billion), Coinbase Global, Inc. ($3.32 billion), Occidental Petroleum Corporation ($2.91 billion), Tractor Supply Company ($2.80 billion), Rivian Automotive, Inc. ($2.44 billion), Moderna, Inc. ($2.41 billion), and United Rentals, Inc. ($2.23 billion). View all of the most shorted stocks. What does it mean to sell short Mirati Therapeutics stock? Short selling MRTX is an investing strategy that aims to generate trading profit from Mirati Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Mirati Therapeutics? A short squeeze for Mirati Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MRTX, which in turn drives the price of the stock up even further. How often is Mirati Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MRTX, twice per month. The most recent reporting period available is December, 31 2023. More Short Interest Resources from MarketBeat Related Companies Intra-Cellular Therapies Short Interest Data Zymeworks Short Interest Data Chimerix Short Interest Data Avid Bioservices Short Interest Data Revance Therapeutics Short Interest Data Checkpoint Therapeutics Short Interest Data Aerovate Therapeutics Short Interest Data 2seventy bio Short Interest Data Acelyrin Short Interest Data Procaps Group Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MRTX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirati Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
